Risk of systemic adverse events similar after bevacizumab, ranibizumab, aflibercept
01 Mar 2021
The risk of acute myocardial infarction (MI), cardiovascular disease (CVD), major bleeding, or all-cause hospitalization is comparable following treatment with intravitreal bevacizumab, ranibizumab, and aflibercept during routine clinical practice, a retrospective cohort study has shown.
Primary immunodeficiency disease (PIDD) and allergies are two groups of conditions related to the immune system. However, they are uniquely different in terms of symptoms and treatment.
Indications/Uses : In combination w/ fulvestrant for postmenopausal women & men w/ hormone-receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer following progression on or after endocrine-based regimen.
Indications/Uses : Active booster immunization for prevention of tetanus, diphtheria & pertussis (whooping cough) in persons ≥4 yr. Passive protection against pertussis in early infancy following maternal immunization during pregnancy. Concomitant w/ inactivated poliomyelitis vaccine as alternative for 5th dose of tetanus, diphtheria & acellular pertussis vaccine (DTaP) in childn 4-6 yr.